SNY

Sanofi ADS
D

SNY

Arincen75/100B
47.010
USD
0.10
(0.21%)
Pre Open·48.030USD+1.020(+2.17%)
Last updated: · Delayed 15 min
Fair value82.55Plus-43%62Price 47.01103
Q4 FY2026 · Earnings report
EPS estimate 0.96Revenue estimate 14.41B
OverviewFinancialsForecastEarningsDividendsCompany

Sanofi ADS net income 1999–2026

Sanofi ADS earned 3.02B EUR in Q3 FY2026, the three months to 30 September 2026, up 7.8% on the same quarter a year before. Sanofi ADS's net income over the last twelve months was 4.18B EUR, down 54.2% on the twelve months before. In fiscal year 2025 it earned 7.81B EUR, up 40.5% on the year before.

Last updated 9 Nov 2026 · Next report 4 Feb 2027

Net income

Net income · +6.2% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM30 Sept 20264.18B-54.16%8.19%50.98B
FY202531 Dec 20257.81B+40.52%16.72%46.72B
FY202431 Dec 20245.56B+2.96%12.55%44.29B
FY202331 Dec 20235.40B-35.49%12.98%41.62B
FY202231 Dec 20228.37B+34.52%20.64%40.56B
FY202131 Dec 20216.22B-49.38%15.89%39.18B
FY202031 Dec 202012.29B+346.41%32.90%37.37B
FY201931 Dec 20192.75B-36.04%7.32%37.63B
FY201831 Dec 20184.31B-48.84%12.07%35.68B
FY201731 Dec 20178.42B+78.72%23.24%36.22B
FY201631 Dec 20164.71B+9.84%13.57%34.70B
FY201531 Dec 20154.29B-2.35%12.30%34.86B
FY201431 Dec 20144.39B+18.14%13.72%32.00B
FY201331 Dec 20133.72B-23.98%11.88%31.29B
FY201231 Dec 20124.89B-13.43%13.59%35.96B
FY201131 Dec 20115.65B+3.27%16.10%35.06B
FY201031 Dec 20105.47B+3.84%16.06%34.04B
FY200931 Dec 20095.27B+36.72%17.12%30.75B
FY200831 Dec 20083.85B-26.83%13.36%28.82B
FY200731 Dec 20075.26B+31.38%18.02%29.21B
FY200631 Dec 20064.01B+77.57%13.58%29.49B
FY200531 Dec 20052.26B+13.69%7.92%28.49B
FY200431 Dec 20041.98B-4.25%12.62%15.72B
FY200331 Dec 20032.07B+17.74%25.80%8.03B
FY200231 Dec 20021.76B+11.05%23.61%7.46B
FY200131 Dec 20011.59B+60.91%24.43%6.49B
FY200031 Dec 2000985.00M+57.60%16.52%5.96B
FY199931 Dec 1999625.00M—11.68%5.35B

Figures in EUR. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Sanofi ADS's profit

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.